Loading...

LSTA LISATA THERAPEUTICS INC Earnings Reports 8-K Filing

LST

LST

LISATA THERAPEUTICS INC

(LSTA)

2023 8-K

Tender Offer Extension

Merger Agreement Announced

Acquisition Update

Collaboration Termination

Acquisition Announcement

Financial Results Report

Investor Presentation Update

New License Agreement

Financial Statements

Product Expansion

Regulation FD Disclosure

Compensatory Arrangements

Financial Statements

Financial Results

Trial Data Release

Collaboration Agreement

Q3 Financial Results

Q2 Financial Results

Annual Meeting of Stockholders

Earnings Reports

Appointment of James Nisco

Financial Results and Prese...

Earnings Reports

Earnings Reports

Termination of Employment

Financial Update

External Links:

Lisata Therapeutics, Inc. reports cash, cash equivalents, and marketable securities of approximately $69.2 million as of December 31, 2022, and provides an update on the Phase 1b trial of LSTA201 for diabetic kidney disease.

AI Assistant

LISATA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.